• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

FluoGuide

43.60 SEK

-0.46 %

Less than 1K followers

FLUO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.46 %
+6.60 %
+21.79 %
+27.11 %
+22.13 %
+4.31 %
-49.07 %
-57.67 %
+386.32 %

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

Read more
Market cap
712.83M SEK
Turnover
288.61K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.8.
2026

Interim report Q2'26

26.11.
2026

Interim report Q3'26

Press release5/28/2026, 4:35 PM

Redeye: FluoGuide (Q1 Review): Catalyst-Heavy Remainder of 2026

FluoGuide
Regulatory press release5/27/2026, 5:09 AM

FluoGuide A/S publishes interim report for Q1 2026

FluoGuide
Press release5/13/2026, 2:45 PM

Invitation to brain surgery simulation

FluoGuide

Join Inderes community

Research, tools and community to support better investment decisions.

FREE account
The market's most popular morning review
Analysts' recommendations and comments
Stock comparison and the investor discussion forum
PREMIUM account
All company reports and analyses
Premium content: model portfolio, insider transactions, Premium articles
Inderes MCP: Inderes data directly into your AI tools
Create account
Press release5/13/2026, 1:17 PM

Invitation to FluoGuide A/S live webcast on 27 May 2026

FluoGuide
Press release4/14/2026, 11:33 AM

Redeye: Fluoguide: Interview with CEO Morten Albrechtsen

FluoGuide
Press release4/10/2026, 6:30 AM

Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, re-presented at SNOG

FluoGuide
Press release4/7/2026, 6:53 AM

Redeye: FluoGuide: Shining light on a mispriced opportunity

FluoGuide
Regulatory press release3/25/2026, 4:44 PM

Minutes from Annual General Meeting in FluoGuide A/S

FluoGuide
Press release3/20/2026, 7:43 AM

BioStock: FluoGuide receives FDA Fast Track designation for FG001 in high-grade glioma

FluoGuide
Regulatory press release3/18/2026, 8:19 PM

FluoGuide receives FDA Fast Track Designation for FG001 in high-grade glioma

FluoGuide
Regulatory press release3/10/2026, 4:50 PM

Notice of Annual General Meeting in FluoGuide A/S

FluoGuide
Press release2/26/2026, 8:45 AM

Redeye: Fluoguide (Q4 Initial take): Key milestones to drive value in 2026

FluoGuide
Press release2/25/2026, 3:33 PM

BioStock: FluoGuide comments on the annual report and road ahead

FluoGuide
Regulatory press release2/25/2026, 6:09 AM

FluoGuide A/S publishes annual report for the fiscal year 2025

FluoGuide
Regulatory press release2/25/2026, 6:07 AM

FluoGuide A/S publishes interim report for Q4 2025

FluoGuide
Regulatory press release2/20/2026, 7:40 PM

FDA clears FluoGuide’s IND for FG001 in High-Grade Glioma; U.S. clinical trial remains on track

FluoGuide
Press release2/19/2026, 8:16 AM

Invitation to FluoGuide A/S (Nasdaq: FLUO) live webcast on 25 February 2026

FluoGuide
Press release1/21/2026, 7:21 AM

FluoGuide submits an IND for FG001, to initiate first U.S. registration trial

FluoGuide
Press release12/19/2025, 10:57 AM

FluoGuide updates IND submission timing for FG001 – trial initiation unaffected

FluoGuide
Press release12/3/2025, 10:29 AM

BioStock: FluoGuide highlights operational progress in Q3

FluoGuide